International non-profit research company IAVI has dosed the first patients in its Phase IIb trial of tuberculosis (TB) vaccine, which, if approved, could be the second to be cleared in more than ...

A clinical trial published in the New England Journal ... reduced the risk of developing drug-resistant tuberculosis (TB), and almost halved adults' and children's risk of developing multidrug ...